EquityEquity - OtherVery High Risk
Direct
NAV (07-May-25)
Returns (Since Inception)
Fund Size
₹195 Cr
Expense Ratio
0.36%
ISIN
INF680P01455
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
09 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-21.24%
— (Cat Avg.)
Equity | ₹186.17 Cr | 95.65% |
Others | ₹8.46 Cr | 4.35% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
HDFC Bank Ltd | Equity | ₹14.51 Cr | 7.46% |
ICICI Bank Ltd | Equity | ₹14.31 Cr | 7.35% |
Bharti Airtel Ltd | Equity | ₹10.27 Cr | 5.28% |
Apollo Hospitals Enterprise Ltd | Equity | ₹9.07 Cr | 4.66% |
The Federal Bank Ltd | Equity | ₹8.58 Cr | 4.41% |
Narayana Hrudayalaya Ltd | Equity | ₹7.98 Cr | 4.10% |
Grasim Industries Ltd | Equity | ₹7.39 Cr | 3.80% |
Blue Star Ltd | Equity | ₹7.25 Cr | 3.73% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹7.25 Cr | 3.72% |
Sundaram Finance Ltd | Equity | ₹7.19 Cr | 3.69% |
Shree Cement Ltd | Equity | ₹7.13 Cr | 3.66% |
Marico Ltd | Equity | ₹6.93 Cr | 3.56% |
REC Ltd | Equity | ₹6.92 Cr | 3.55% |
Godrej Agrovet Ltd Ordinary Shares | Equity | ₹6.49 Cr | 3.33% |
UltraTech Cement Ltd | Equity | ₹6.17 Cr | 3.17% |
Bajaj Finance Ltd | Equity | ₹5.96 Cr | 3.06% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹5.77 Cr | 2.97% |
Vijaya Diagnostic Centre Ltd | Equity | ₹5.29 Cr | 2.72% |
Amber Enterprises India Ltd Ordinary Shares | Equity | ₹5.23 Cr | 2.69% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹4.94 Cr | 2.54% |
JK Cement Ltd | Equity | ₹4.91 Cr | 2.52% |
BSE Ltd | Equity | ₹4.45 Cr | 2.29% |
Can Fin Homes Ltd | Equity | ₹4.24 Cr | 2.18% |
Radico Khaitan Ltd | Equity | ₹4.1 Cr | 2.11% |
Divi's Laboratories Ltd | Equity | ₹3.9 Cr | 2.00% |
Godrej Consumer Products Ltd | Equity | ₹3.73 Cr | 1.92% |
DOMS Industries Ltd | Equity | ₹3.7 Cr | 1.90% |
Fortis Healthcare Ltd | Equity | ₹3.45 Cr | 1.77% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.94 Cr | 1.51% |
Abbott India Ltd | Equity | ₹2.7 Cr | 1.39% |
Net Receivables / (Payables) | Cash | ₹1.21 Cr | 0.62% |
Hindustan Aeronautics Ltd Ordinary Shares | Equity | ₹0.68 Cr | 0.35% |
Large Cap Stocks
40.91%
Mid Cap Stocks
33.19%
Small Cap Stocks
21.56%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Financial Services | ₹66.17 Cr | 34.00% |
Healthcare | ₹46.03 Cr | 23.65% |
Basic Materials | ₹25.6 Cr | 13.15% |
Consumer Defensive | ₹21.25 Cr | 10.92% |
Industrials | ₹11.62 Cr | 5.97% |
Communication Services | ₹10.27 Cr | 5.28% |
Consumer Cyclical | ₹5.23 Cr | 2.69% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since December 2024
Since December 2024
ISIN INF680P01455 | Expense Ratio 0.36% | Exit Load 1.00% | Fund Size ₹195 Cr | Age 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark Nifty 500 TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Your principal amount will be at Very High Risk
EquityEquity - OtherVery High Risk
Direct
NAV (07-May-25)
Returns (Since Inception)
Fund Size
₹195 Cr
Expense Ratio
0.36%
ISIN
INF680P01455
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
09 Dec 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-21.24%
— (Cat Avg.)
Equity | ₹186.17 Cr | 95.65% |
Others | ₹8.46 Cr | 4.35% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
HDFC Bank Ltd | Equity | ₹14.51 Cr | 7.46% |
ICICI Bank Ltd | Equity | ₹14.31 Cr | 7.35% |
Bharti Airtel Ltd | Equity | ₹10.27 Cr | 5.28% |
Apollo Hospitals Enterprise Ltd | Equity | ₹9.07 Cr | 4.66% |
The Federal Bank Ltd | Equity | ₹8.58 Cr | 4.41% |
Narayana Hrudayalaya Ltd | Equity | ₹7.98 Cr | 4.10% |
Grasim Industries Ltd | Equity | ₹7.39 Cr | 3.80% |
Blue Star Ltd | Equity | ₹7.25 Cr | 3.73% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹7.25 Cr | 3.72% |
Sundaram Finance Ltd | Equity | ₹7.19 Cr | 3.69% |
Shree Cement Ltd | Equity | ₹7.13 Cr | 3.66% |
Marico Ltd | Equity | ₹6.93 Cr | 3.56% |
REC Ltd | Equity | ₹6.92 Cr | 3.55% |
Godrej Agrovet Ltd Ordinary Shares | Equity | ₹6.49 Cr | 3.33% |
UltraTech Cement Ltd | Equity | ₹6.17 Cr | 3.17% |
Bajaj Finance Ltd | Equity | ₹5.96 Cr | 3.06% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹5.77 Cr | 2.97% |
Vijaya Diagnostic Centre Ltd | Equity | ₹5.29 Cr | 2.72% |
Amber Enterprises India Ltd Ordinary Shares | Equity | ₹5.23 Cr | 2.69% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹4.94 Cr | 2.54% |
JK Cement Ltd | Equity | ₹4.91 Cr | 2.52% |
BSE Ltd | Equity | ₹4.45 Cr | 2.29% |
Can Fin Homes Ltd | Equity | ₹4.24 Cr | 2.18% |
Radico Khaitan Ltd | Equity | ₹4.1 Cr | 2.11% |
Divi's Laboratories Ltd | Equity | ₹3.9 Cr | 2.00% |
Godrej Consumer Products Ltd | Equity | ₹3.73 Cr | 1.92% |
DOMS Industries Ltd | Equity | ₹3.7 Cr | 1.90% |
Fortis Healthcare Ltd | Equity | ₹3.45 Cr | 1.77% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.94 Cr | 1.51% |
Abbott India Ltd | Equity | ₹2.7 Cr | 1.39% |
Net Receivables / (Payables) | Cash | ₹1.21 Cr | 0.62% |
Hindustan Aeronautics Ltd Ordinary Shares | Equity | ₹0.68 Cr | 0.35% |
Large Cap Stocks
40.91%
Mid Cap Stocks
33.19%
Small Cap Stocks
21.56%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Financial Services | ₹66.17 Cr | 34.00% |
Healthcare | ₹46.03 Cr | 23.65% |
Basic Materials | ₹25.6 Cr | 13.15% |
Consumer Defensive | ₹21.25 Cr | 10.92% |
Industrials | ₹11.62 Cr | 5.97% |
Communication Services | ₹10.27 Cr | 5.28% |
Consumer Cyclical | ₹5.23 Cr | 2.69% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since December 2024
Since December 2024
ISIN INF680P01455 | Expense Ratio 0.36% | Exit Load 1.00% | Fund Size ₹195 Cr | Age 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark Nifty 500 TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments